MAPT and Alzheimer disease: Compared to free quercetin, plasma sEVs loaded with quercetin improved the drug bioavailability in AD and further relieved the symptoms of AD in this model by inhibiting the cyclin-dependent kinase 5-mediated phosphorylation of tau and reducing formation of insoluble neurofibrillary tangles, suggesting its potential therapeutic benefit in AD.